Literature DB >> 30058426

Decreased apolipoprotein A4 and increased complement component 3 as potential markers for papillary thyroid carcinoma: A proteomic study.

Reyhaneh Farrokhi Yekta1, Afsaneh Arefi Oskouie2, Mostafa Rezaei Tavirani1, Mohammad R Mohajeri-Tehrani3, Ahmad R Soroush4.   

Abstract

BACKGROUND: : Thyroid carcinomas have comprised the fastest rising incidence of cancer in the past decade. Currently, the diagnosis of thyroid tumors is performed by the fine-needle aspiration biopsy (FNAB) method, which still holds some challenges and limitations, mostly in discriminating malignant and benign lesions. Therefore, the development of molecular markers to distinguish between these lesion types are in progress.
METHODS: : A 2D-PAGE separation of proteins was performed followed by tandem mass spectrometry with the aim of discovering potential serum protein markers for papillary thyroid carcinoma and multinodular goiter. Protein-protein interaction network analysis revealed the most important pathways involved in the progression of papillary thyroid cancer. The enzyme-linked immunosorbent assay method was used to confirm a part of the results.
RESULTS: : The significantly altered proteins included C3, C4A, GC, HP, TTR, APOA4, APOH, ORM2, KRT10, AHSG, IGKV3-20, and IGKC. We also confirmed that increased complement component 3 and decreased apolipoprotein A4 occurred in papillary thyroid cancer. Network investigations demonstrated that complement activation cascades and PPAR signaling might play a role in the pathogenesis of thyroid cancer.
CONCLUSION: : The results demonstrated that serum proteomics could serve as a viable method for proposing novel potential markers for thyroid tumors. Surely, further research must be performed in larger cohorts to validate the results.

Entities:  

Keywords:  Electrophoresis; mass spectrometry; proteomics; serum; thyroid cancer

Mesh:

Substances:

Year:  2018        PMID: 30058426     DOI: 10.1177/1724600818787752

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  4 in total

1.  Salivary Proteome, Inflammatory, and NETosis Biomarkers in Older Adult Practitioners and Nonpractitioners of Physical Exercise.

Authors:  Valeria B Pacheco; Giulia Nery; Larissa L Fernandes; Thais V Santana; Manuel Jimenez; Leandro Borges; Elaine Hatanaka; Pedro Braga; Fernanda R Monteiro; Jônatas B Amaral; Luana S Alves; André L L Bachi; Sérgio Gomes da Silva; Alexander Birbrair; Débora Heller
Journal:  Oxid Med Cell Longev       Date:  2022-04-23       Impact factor: 7.310

2.  Artificial intelligence defines protein-based classification of thyroid nodules.

Authors:  Yaoting Sun; Sathiyamoorthy Selvarajan; Zelin Zang; Wei Liu; Yi Zhu; Hao Zhang; Wanyuan Chen; Hao Chen; Lu Li; Xue Cai; Huanhuan Gao; Zhicheng Wu; Yongfu Zhao; Lirong Chen; Xiaodong Teng; Sangeeta Mantoo; Tony Kiat-Hon Lim; Bhuvaneswari Hariraman; Serene Yeow; Syed Muhammad Fahmy Alkaff; Sze Sing Lee; Guan Ruan; Qiushi Zhang; Tiansheng Zhu; Yifan Hu; Zhen Dong; Weigang Ge; Qi Xiao; Weibin Wang; Guangzhi Wang; Junhong Xiao; Yi He; Zhihong Wang; Wei Sun; Yuan Qin; Jiang Zhu; Xu Zheng; Linyan Wang; Xi Zheng; Kailun Xu; Yingkuan Shao; Shu Zheng; Kexin Liu; Ruedi Aebersold; Haixia Guan; Xiaohong Wu; Dingcun Luo; Wen Tian; Stan Ziqing Li; Oi Lian Kon; Narayanan Gopalakrishna Iyer; Tiannan Guo
Journal:  Cell Discov       Date:  2022-09-06       Impact factor: 38.079

3.  Construction of 2DE Patterns of Plasma Proteins: Aspect of Potential Tumor Markers.

Authors:  Stanislav Naryzhny; Natalia Ronzhina; Elena Zorina; Fedor Kabachenko; Nikolay Klopov; Victor Zgoda
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

4.  Distinguishing Benign and Malignant Thyroid Nodules and Identifying Lymph Node Metastasis in Papillary Thyroid Cancer by Plasma N-Glycomics.

Authors:  Zejian Zhang; Karli R Reiding; Jianqiang Wu; Zepeng Li; Xiequn Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-25       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.